Egyptian biotech Reme-D raises $500K to scale room-temperature diagnostics across Africa

Egyptian biotech startup Reme-D has closed a $500,000 funding round from the Global Innovation Fund to expand its molecular diagnostics platform across Africa and the Middle East. The company makes PCR testing kits that stay stable at room temperature, removing the need for expensive cold-chain storage.

Founded in 2022, Reme-D uses nanotechnology and freeze-drying techniques to create diagnostic tests that work reliably in places with poor infrastructure. The technology cuts operational costs by up to 40% while reducing waste and improving accuracy in regions where electricity supply is inconsistent.

What will the capital be used for?

The fresh funding will help Reme-D execute several growth plans:

• Expand commercially into Nigeria and Libya
• Scale up manufacturing capabilities
• Advance research into genetic diseases, cancer diagnostics, and maternal health testing

The company plans to build on its existing presence across Egypt, Iraq, Sudan, and Kenya, where it already serves 92 healthcare facilities.

Why does it matter?

Reme-D's technology addresses a major problem in healthcare delivery across developing regions. Traditional PCR tests require constant refrigeration, which is expensive and often impossible in areas with unreliable power grids.

The company's room-temperature stable tests have already shown strong results. They process about 50,000 patient tests monthly and have reduced testing time by up to 70% in some applications. This speed and reliability can be critical for diagnosing infectious diseases and other conditions that require quick treatment decisions.

The context

Reme-D represents a growing trend of locally developed healthcare technologies designed for real-world constraints in emerging markets. Instead of adapting Western technologies, companies like Reme-D are building solutions from the ground up to work in challenging environments.

The Global Innovation Fund's investment signals continued interest in healthcare startups that can improve access to diagnostics in underserved populations. As the company expands into larger markets like Nigeria, it will test whether its approach can scale beyond the initial four-country footprint it has established since 2022.